Plain-English translation of NCT07253311 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are testing a new rapid diagnostic device called NG-Test® Candida auris that can quickly detect a serious fungal infection or colonization (when germs live on your skin without causing illness yet). This test is faster than traditional methods, which could help hospitals identify and control the spread of this fungal infection more quickly.
Candida auris is a dangerous fungal infection that spreads easily in hospital settings and is hard to treat. A faster, more reliable way to detect it could help hospitals quickly identify infected or colonized patients and prevent the infection from spreading to others.
You likely qualify if…
You likely don't qualify if…
You would not need to visit a clinic or take any medication. Researchers will use samples (isolates) that were already collected during your routine hospital care. Your sample will be tested with the new rapid test device and compared to the standard laboratory method. All results will be stored securely using a code number to protect your privacy.
AI-generated summary from trial data · Oct 7, 2026 · Not medical advice
Greece
Collaborators
NG Biotech, Commissariat A L'energie Atomique
Enrollment target
~554 participants
Started
May 2026
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Thierry NAAS, PhD
Assistance Publique - Hôpitaux de Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.